000			01448 a2200421 4500
005			20250514020052.0
264		0	_c20020110
008			200201s 0 0 eng d
022			_a1521-6616
024	7		_a10.1006/clim.2001.5132 _2doi
040			_aNLM _beng _cNLM
100	1		_aRazvi, S
245	0	0	_aOutcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. _h[electronic resource]
260			_bClinical immunology (Orlando, Fla.) _cDec 2001
300			_a284-8 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aChild
650	0	4	_aDrug Contamination
650	0	4	_aHepatitis C _xdrug therapy
650	0	4	_aHumans
650	0	4	_aImmunoglobulins, Intravenous _xadverse effects
650	0	4	_aImmunologic Deficiency Syndromes _xdrug therapy
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aRibavirin _xtherapeutic use
650	0	4	_aSurveys and Questionnaires
650	0	4	_aTreatment Outcome
700	1		_aSchneider, L
700	1		_aJonas, M M
700	1		_aCunningham-Rundles, C
773	0		_tClinical immunology (Orlando, Fla.) _gvol. 101 _gno. 3 _gp. 284-8
856	4	0	_uhttps://doi.org/10.1006/clim.2001.5132 _zAvailable from publisher's website
999			_c11640306 _d11640306